WO2009116884A2 - Human papillomavirus detection kit - Google Patents
Human papillomavirus detection kit Download PDFInfo
- Publication number
- WO2009116884A2 WO2009116884A2 PCT/PT2009/000015 PT2009000015W WO2009116884A2 WO 2009116884 A2 WO2009116884 A2 WO 2009116884A2 PT 2009000015 W PT2009000015 W PT 2009000015W WO 2009116884 A2 WO2009116884 A2 WO 2009116884A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- restriction
- dna
- assay
- rsal
- Prior art date
Links
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 117
- 238000001514 detection method Methods 0.000 title claims abstract description 11
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 239000012634 fragment Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000003205 genotyping method Methods 0.000 claims abstract description 18
- 230000003321 amplification Effects 0.000 claims abstract description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 6
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 6
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 13
- 239000000499 gel Substances 0.000 claims description 13
- 229920002401 polyacrylamide Polymers 0.000 claims description 10
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 claims description 8
- 230000029087 digestion Effects 0.000 claims description 8
- 208000016861 hereditary angioedema type 3 Diseases 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 6
- 229920000936 Agarose Polymers 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013642 negative control Substances 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 5
- 101150075239 L1 gene Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 30
- 238000003752 polymerase chain reaction Methods 0.000 description 28
- 108091093088 Amplicon Proteins 0.000 description 9
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 7
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000012405 in silico analysis Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 101150034230 LI gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
Definitions
- the present invention relates to a methodology and a diagnostic kit for the detection and identification of all mucosal human papillomavirus (HPV).
- HPV mucosal human papillomavirus
- HPV human papillomavirus
- HPVs are a heterogeneous group of double stranded, non-enveloped DNA viruses of the Papillomaviridae family. Al present, more than 100 HPV types have been identified worldwide, approximately 50 of which infecting the anogcnital epithelium. According to the recent classification from the International Agency for Research on Cancer (IARC), the mucosal HPV types are divided into four groups based on their oncogenic activity: high-risk (HPVs 16, 18, 31. 33. 35, 39, 45, 51, 52.
- high-risk HPVs 16, 18, 31. 33. 35, 39, 45, 51, 52.
- H PV testing was firstly introduced to compensate the poor sensitivity and specificity of the Pap .smear cytology (Papanicolaou test).
- HPV-DNA is usually detected by a non-PCR-hased assay which consists on a signal-amplifying hybridization method, the Hyhrid Capture System Il (HClI) (Qiagcu Gailhersburg Inc., MD, USA, previously Digcne Corp.).
- HlI Hyhrid Capture System Il
- This methodology (US4.849.332) allows the detection of 13 probable/ high-risk types and 5 low-risk types using two different cocktails of RNA probes, in two separate reactions.
- HC U presents important limitations: it does not provide information about the specific type of HPV that is detected, it does not detect all known probable/high-risk types, it is less sensitive than Polymerase Chain Reaction (PCR) methodologies and the cross- a activity of the two cocktail probes reduces the clinical relevance of a positive result.
- PCR Polymerase Chain Reaction
- PCR polymerase chain reaction
- Genotyping of HPV can be done by type-specific PCR using primers that recognize only one specific type.
- An alternative approach is the use of universal primers, which are directed to a highly conserved region of rhe HPV LI gene and are virtually capable of detecting all mucosal HPV types in a single PCR reaction.
- the papillomaviruses are subsequently typed through analysis of the sequence of the amplified fragment by different methods, such as DNA sequencing, nucleic acid hybridization, and restriction fragment length polymorphism analysis (RFLP).
- RFLP restriction fragment length polymorphism analysis
- PCR using consensus primers with subsequent restriction fragment length polymorphism analysis has been demonstrated to be a simple, sensitive and financially advantageous methodology to detect and characterize HPV-DNA in clinical specimens.
- PCR-RFLP assays previously described (Lungu et al. MoI Cell Probes. 1992, 6:145-152 - US5.814.448; Kay et al., J. Virol. Methods. 2002, 159:159-170; Naqvi et al. J. Virol. Methods. 2004, 117:91-95: Santiago et al. J. Clin. Virol.
- HPV 18 and 68, HPV 18 and 70, HPV 18 and 42, HPV 31 and 58, HPV 33 and 13, HPV 51 and 83, HPV 56 and 11, HPV 58 and 62, HPV 82 and 53, HPV 6 and 64, HPV 61 and 84 are indistinguishable on agarose or polyacrylamide gels.
- the present invention aims:
- Figure 1 shows the sequences identification numbers of the primers used in the present invention.
- Figure 2 shows a scheme for mucosal HPV genotyping after RFLP analysis of MY09/11 amplicons using Pstl, HaelH, Ddel, and Rsal restriction endonucleases.
- Figure 3 shows a validation of RFLP restriction reactions on 10% polyacrylamide gel
- FIG. 4 shows theRFLP patterns of MY09/11 PCR products of HPV 16 (a), HPV 58
- Lane Ml 50 bp DNA molecular weight marker
- Lane P undigested MY09/11 PCR amplicon
- Lane M2 25 bp DNA molecular weight marker. description of the invention
- the present invention relates to a method and a diagnostic kit for detection and/or typing of all mucosal human papillomavirus (HPV).
- HPV mucosal human papillomavirus
- HPV type identification is performed by comparison of RFLP patterns obtained for each restriction enzyme with the reference RFLP patterns (Table 1).
- a genotyping scheme ( Figure 2) was included, which allows the identification of HPV types in two easy steps: analyzing of occurrence/ non-occurrence of the Pstl, HaeIII Ddel and Rsal restriction reactions and subsequent comparison of the restriction fragments obtained by Rsal. Therefore, using this scheme, the RFLP patterns are subsequently analyzed in the following order: Pstl ⁇ HaeIII ⁇ Ddel - ⁇ Rsal. At the end of the scheme, comparison is made between the restriction fragments obtained by Rsal restriction with the expected sizes defined for each HPV type.
- the present invention has resulted from an extensive in silico analysis of all known mucosal HPV DNA sequences for the presence of restriction endonuclease cleavage sites within the region of Ll that is amplified using universal MY primers, as follows: 1) A total of 296 DNA sequences deposited in GenBank, corresponding to 49 genital HPV types (6, 11, 13, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, 102, and 106) and 2 HPV subtypes (HPV 55 and 64) were aligned using the 'Alignment tool' of CLC Free Workbench program, version 3.2 (CLC bio, Denmark). Subs
- a file B was created, which included the set of following restriction en- donucleases: Pstl (5'-CTGCA/G-3'), HaeIII (5'-GG/CC-3'), Rsal (5'-GT/AC-3') and Ddel (5'-C/TNAG-3').
- This set of enzymes was pre-selected through an in silico analysis and allows identification of the 49 MY09/11 segments corresponding to the 49 reference HPV types.
- each box represents a restriction reaction using a specific enzyme.
- Draw lines represent the possible results when restriction does not occur, whereas dashed lines represent the possible results when restriction occurs. In two particular situations (designated by 1 and 2), draw lines also represent the possible results when restriction reaction originates an RFLP- fragment larger than 420 bp.
- HPV type is identified in two easy steps: (1) sequential analysis of occurrence/ non-occurrence of Pstl, Haelll, Ddel and Rsal restriction reactions and (2) subsequent comparison of the restriction fragments obtained by Rsal digestion with the expected sizes (in brackets) defined for each HPV type by in silico analysis.
- HPV type can be identified by comparison of the restriction fragment sizes obtained by Ddel or HaeIII restriction digestion ('confirmation pattern').
- a HPV type it is possible to confirm it, comparing all the RFLP-patterns obtained with data described in Table 1.
- One of the weak points of known HPV diagnostic assays is the appearance of false negatives, due to the poor quality of DNA or by the presence of PCR inhibitors.
- a control consisting of parallel amplification of the patient's own DNA is used to ensure the quality of DNA sample.
- Primers Beta 1 and Beta 2 (SEQ ID NO 21 and 22) were designed for amplification of a 501 bp fragment from beta-globin gene.
- any sequence fragment from human DNA can be used as target for this purpose.
- Betal/2 amplicon is cleaved by the whole spectrum of selected restriction enzymes when optimal conditions are achieved, originating the following restriction fragments: Pstl: 322 bp + 179 bp; HaeIII: 279 bp + 222 bp; Ddel: 271 bp + 198 bp + 32 bp; Rsal: 251 bp + 210 bp + 40 (see Figure 3).
- the size of these fragments does not coincide with any of the fragments listed in Table 1.
- HPV typing assays like hybridization with type-specific probes, type-specific PCR, microarray methodologies: 1) it detects a higher number of HPV types (49 HPV types and 2 HPV subtypes); 2) it allows the individual detection of all known and unknown HPV types; and 3) it can be performed using standard laboratorial equipment and in settings of poor financial resources.
- kits for identification of HPV types comprises the following components:
- the above-mentioned kit also comprises a standard nucleic acid amplification mix with a pair of primers to test DNA integrity.
- the said kit may also comprise a positive and negative control sample.
- kit also may include instructions for its use.
- Examples EXAMPLE 1 DNA extraction from cells of the cervix uteri - Cervical cells collected from the cervix uteri, using a brush or spatula, were resuspended in PreservCyt solution (Cytyc Corporation. Boxborough, MA. USA). An aliquot of 5ml was cen- trifuged at 10.000 rpm for 15 min. The pelleted cells were lysed in a Tris-buffered solution (0.3M NaCl, 1OmM EDTA, 10mM Tris pH 7.5), containing 0.5% SDS and 0.5 ⁇ g/ ⁇ l of proteinase K, at 56 oC. The DNA was purified by standard phenol/ chloroform extraction and ethanol precipitation.
- EXAMPLE 2 Human papillomavirus detection - HPV DNA was detected by PCR using the degenerate consensus primers MY09/11 (Manos et al. Cold Spring Harbor Press. 1989, 7:209-214), which amplify a region of 449-458 nucleotides (depending on HPV type) of the highly conserved Ll ORF.
- PCR amplification was carried out with lOOng of template DNA in 1x PCR Buffer (Biotools, Madrid, Spain), containing 1.5mM MgC12, 12.5 pmol of each primer MY09 and MYl 1 (SEQ ID NO 1 and 2), 200 uM of each deoxynucleotide triphosphate and 1 unit of Taq DNA polymerase (Biotools, Madrid, Spain).
- Thermal cycling was performed in a Perkin-Elmer 9600 (PerkinElmer, MA, USA) as follows: denaturation of DNA template at 95 oC for 5 min, followed by 45 cycles of 94 oC for 60 sec, 55 oC for 60 sec, and 72 oC for 60 sec, and a final extension step at 72 oC for 8 min.
- Betal and Beta2 SEQ ID NO 21 and 22.
- the PCR conditions were the same as described for HPV detection. All PCR reactions were carried out under conditions that minimize sample cross-contamination. DNA from HeLa and CaSki cell lines was used as positive control. A negative control containing all PCR reagents, except the DNA, was added to monitor contamination.
- the amplified DNA was analyzed in a horizontal 2% agarose gel, pre-stained with Gel Star (Cambrex Bio Science Rockland, Inc., ME, USA) and visualized on a UV screen.
- EXAMPLE 3 Human papillomavirus genotyping - MY09/11-positive cases were typed by RFLP analysis in 4 independent reactions. Each restriction reaction was performed in a final volume of 20 ⁇ l, using 1 ⁇ g of MY09/11 PCR product, 2 ⁇ l of 10x recommended restriction buffer, and 10 units of the following restriction en- donucleases: Pstl (Qbiogene, CA, USA), HaeIII (Fermentas Inc., Canada), Ddel (Qbiogene, CA, USA) and Rsal (Fermentas Inc., Canada), according to the manufacturers' instructions. Reactions took place at 37 oC for 1 h.
- EXAMPLE 4 Validation of RFLP restriction reaction - To test the efficacy of each enzyme and to avoid the misidentification of types due to partial digestion, an additional restriction reaction was performed, in which MY09/11 PCR products and a control DNA (PCR product of Beta-globin fragment amplification) were digested together. Each restriction reaction was performed in a final volume of 20 ⁇ l, using 1 ⁇ g of MY09/11 PCR product. 1 ⁇ g of Betal/2 amplicon, 2 ⁇ l of 10x recommended restriction buffer, and 20 units of each restriction endonuclease, according to the conditions described in Example 3.
- EXAMPLE 5 Clinical validation of the present invention - To confirm the reliability of the present PCR-RFLP based methodology and the applicability of the HPV typing scheme in HPV identification, two different experiments were performed. The first study was carried out, in a blind fashion, on pre-selected HPV positive clinical samples, in which 27 different mucosal HPV types had been previously identified by PCR with MY09/11 primers and DNA sequencing (HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 44, 45, 52, 53, 56, 58, 59, 61, 62, 66, 67, 70, 71, 73, 81, 83, 84, and 102). In all samples, PCR-RFLP data consistently matched the DNA sequencing results. Figure 4 shows the RFLP patterns of some HPV types (HPV 16, HPV 58 and HPV 102).
- PCR products were purified from agarose gel using a PCR clean-up Gel extraction Kit (NucleoSpin® Extract II, Macherey-Nagel, Ge ⁇ nany) and cloned. At least, five fragments of each amplicon were sequenced. Forward and reverse sequencing reactions were carried out using 20 ng of template DNA from PCR amplimers and 20 ⁇ M of the MY09 and MYl 1 primers, respectively. Automated DNA sequencing was performed by Eurofins MWG Operon (Ebersberg, Germany). Sequences obtained were compared with all sequences available in Gen-Bank database. HPV type was identified based on >98% sequence homology over 449-458 nucleotides. Table 2 shows the comparative genotyping results of HPV-positive clinical samples using RFLP analysis and DNA sequencing/ cloning analysis of MY09/1 1 PCR products. [46] Table 2:
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a method and a diagnostic kit for detection and typing of all human papillomavirus (HPV) comprising: nucleic acid amplification of a region of L1 gene using universal HPV primers, treating of the amplified fragment in four independent restriction reactions with different enzymes, namely Pstl. Haelll, Ddel and Rsal, and identification of HPV type by comparison of RFLP patterns with the reference patterns of known genotypes using an HPV genotyping scheme.
Description
Description Human Papillomavirus Detection Kit
Field of the invention
[1] The present invention relates to a methodology and a diagnostic kit for the detection and identification of all mucosal human papillomavirus (HPV). State-of-the-art
[2] Ii is presently well established and globally accepted that the persisting infection with a human papillomavirus (HPV) of high-risk type is the main cause of cervical cancer. HPVs are a heterogeneous group of double stranded, non-enveloped DNA viruses of the Papillomaviridae family. Al present, more than 100 HPV types have been identified worldwide, approximately 50 of which infecting the anogcnital epithelium. According to the recent classification from the International Agency for Research on Cancer (IARC), the mucosal HPV types are divided into four groups based on their oncogenic activity: high-risk (HPVs 16, 18, 31. 33. 35, 39, 45, 51, 52. 56, 58, and 59), probable high-risk (IlP Vs 26, 53. 66, 68, 73. 82), low-risk (HPVs 6. 11. 13, 40, 42. 43. 44. 54, 61, 70, 72, 81 and 89) and undetermined-risk types (HPVs 30, 32, 34, 62, 67, 69, 71. 74. 83. 84, 85. 86, 87, 90, 91). Due to the existing oncogenic differences between mucosatropic HPVs. it is clinically important not only to detect, but also to accurately identify different HPV types.
[3] H PV testing was firstly introduced to compensate the poor sensitivity and specificity of the Pap .smear cytology (Papanicolaou test). At the present time, in the majority of the cervical screening programs around the world, HPV-DNA is usually detected by a non-PCR-hased assay which consists on a signal-amplifying hybridization method, the Hyhrid Capture System Il (HClI) (Qiagcu Gailhersburg Inc., MD, USA, previously Digcne Corp.). This methodology (US4.849.332) allows the detection of 13 probable/ high-risk types and 5 low-risk types using two different cocktails of RNA probes, in two separate reactions.
[4] Although, being the only test approved by the Food and Drug Administration (FDA),
HC U presents important limitations: it does not provide information about the specific type of HPV that is detected, it does not detect all known probable/high-risk types, it is less sensitive than Polymerase Chain Reaction (PCR) methodologies and the cross- a activity of the two cocktail probes reduces the clinical relevance of a positive result.
[5] In order to improve the quality of HPV -detection, new methodologies have been developed, mainly carried out using the polymerase chain reaction (PCR). Genotyping of HPV can be done by type-specific PCR using primers that recognize only one specific type. An alternative approach is the use of universal primers, which are directed to a highly conserved region of rhe HPV LI gene and are virtually capable of
detecting all mucosal HPV types in a single PCR reaction. The papillomaviruses are subsequently typed through analysis of the sequence of the amplified fragment by different methods, such as DNA sequencing, nucleic acid hybridization, and restriction fragment length polymorphism analysis (RFLP).
[6] PCR using consensus primers with subsequent restriction fragment length polymorphism analysis (PCR-RFLP) has been demonstrated to be a simple, sensitive and financially advantageous methodology to detect and characterize HPV-DNA in clinical specimens. However. PCR-RFLP assays previously described (Lungu et al. MoI Cell Probes. 1992, 6:145-152 - US5.814.448; Kay et al., J. Virol. Methods. 2002, 159:159-170; Naqvi et al. J. Virol. Methods. 2004, 117:91-95: Santiago et al. J. Clin. Virol. 2006, 25:89-97; WO2006/015991) present important limitations, since they often make use of a large number of restriction endonucleases or the set of selected enzymes do not allow the individual identification of all mucosal types and/or discrimination between high- and low-risk types. Furthermore, different HPV types usually present identical or similar RFLP patterns. In the documentWO2006/015991, although a reasonable discrimination between high- and low-risk types is achieved using a single restriction enzyme (CviRI), some HPV types still present the same RFLP patterns (for instance, HPV 11 and 30, and HPV 44 and 55). Moreover, several HPV types (HPV 18 and 68, HPV 18 and 70, HPV 18 and 42, HPV 31 and 58, HPV 33 and 13, HPV 51 and 83, HPV 56 and 11, HPV 58 and 62, HPV 82 and 53, HPV 6 and 64, HPV 61 and 84) are indistinguishable on agarose or polyacrylamide gels.
[7] The same is observed in the US5.814.448, where 3 restriction endonucleases (Haelll,
Rsal, and Pstl) are used together in a single-tube restriction reaction. In this assay, different types of HPV (for instance, HPV 18 and 45, HPV 30 and 53, HPV 66 and 74, HPV 82 and 83, HPV 82 and 85, HPV 73 and 106, and HPVs 31, 54 and 97) display identical or similar cleavage patterns.
[8] An additional disadvantage of all above-mentioned PCR-RFLP assays regards the complexity and time-consuming procedures associated with the interpretation of RFLP patterns and corresponding HPV type identification.
[9] The present invention aims:
- to provide a simple and cost-effective methodology for individual identification of all known and unknown mucosal HPV types, which can be performed using standard laboratorial equipment and in settings of poor financial resources;
- to provide the minimum number of restriction endonucleases that allow the complete and individual genotyping of all known mucosal HPV types;
- to provide an accurate and time-effective scheme for the interpretation of RFLP patterns and HPV type identification;
- to provide a diagnostic kit comprising all reagents for the amplification of the HPV
DNA from a biological sample and subsequent RFLP analysis, an HPV genotyping scheme for an accurate interpretation of the results and instructions for using the kit. Brief description of the drawings
LlO] Figure 1 shows the sequences identification numbers of the primers used in the present invention.
[11] Figure 2 shows a scheme for mucosal HPV genotyping after RFLP analysis of MY09/11 amplicons using Pstl, HaelH, Ddel, and Rsal restriction endonucleases.
[ 12] Figure 3 shows a validation of RFLP restriction reactions on 10% polyacrylamide gel
(RFLP patterns from co-digestion of MY09/1 IPCR products of HPV 16 and Betal/2 amplicon). Asterisks indicate fragments from Betal/2 amplicon restriction. Lane Ml = 50 bp DNA molecular weight marker; Lane M2 = 25 bp DNA molecular weight marker.
[13] Figure 4 shows theRFLP patterns of MY09/11 PCR products of HPV 16 (a), HPV 58
(b) and HPV102 (c). Lane Ml = 50 bp DNA molecular weight marker; Lane P = undigested MY09/11 PCR amplicon; Lane M2 = 25 bp DNA molecular weight marker. description of the invention
[14] The present invention relates to a method and a diagnostic kit for detection and/or typing of all mucosal human papillomavirus (HPV).
[ 151 The method of the present invention comprises the following steps:
(I) Amplification of HPV DNA: DNA extracted from clinical samples is amplified using a set of universal primers, which are directed to highly conserved regions of the HPV Ll gene and are potentially capable of detecting all HPV types.
[16] Although the standard PCR was the preferred amplification method used in the present invention, mainly because it is a well-known, practical and cost-effective methodology, any of the other amplification methodologies known in the art can be performed (ligase chain reaction, transcription-based amplification system, or PCR using low-temperature ready-to-use moderately thermostable DNA polymerase system).
[17] In an embodiment of the present invention, universal primers MY09/MY 11 (SEQ ID
NO: 1 and 2) (Manos et al. Cold Spring Harbor Press. 1989, 7:209-214) or PGMY09/11 primer system (SEQ ID NO: 3 to 20) (Gravitt et al. J Clin Microbiol. 2000, 38:357-361) have been used.
[18] (H) Restriction analysis of amplified DNA : The resulting product of HPV DNA amplified in I) is subsequently analyzed in four independent restriction reactions, namely Ddel (5'-C/TNAG-3'), Pstl (5'-CTGCA/G-3'X HaeIII (5'-GG/CC-3') and Rsal (5'-GT/AC-3'). However, any other restriction endonucleases that recognize the same
sequences (isoschizomers) can be used.
[19] (III) Identification of HPV type : The restrictions products obtained in II) are subsequently analyzed in agarose or polyacrylaraide gels pre-stained with a nucleic acid stain for DNA (EtBr. SYBR green, Gel star, etc) or using any other assay which have been proposed for DNA fragment size measurements.
[20] HPV type identification is performed by comparison of RFLP patterns obtained for each restriction enzyme with the reference RFLP patterns (Table 1).
[21] In the present invention, a genotyping scheme (Figure 2) was included, which allows the identification of HPV types in two easy steps: analyzing of occurrence/ non-occurrence of the Pstl, HaeIII Ddel and Rsal restriction reactions and subsequent comparison of the restriction fragments obtained by Rsal. Therefore, using this scheme, the RFLP patterns are subsequently analyzed in the following order: Pstl → HaeIII → Ddel -→ Rsal. At the end of the scheme, comparison is made between the restriction fragments obtained by Rsal restriction with the expected sizes defined for each HPV type.
[22] The present invention has resulted from an extensive in silico analysis of all known mucosal HPV DNA sequences for the presence of restriction endonuclease cleavage sites within the region of Ll that is amplified using universal MY primers, as follows: 1) A total of 296 DNA sequences deposited in GenBank, corresponding to 49 genital HPV types (6, 11, 13, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, 102, and 106) and 2 HPV subtypes (HPV 55 and 64) were aligned using the 'Alignment tool' of CLC Free Workbench program, version 3.2 (CLC bio, Denmark). Subsequently, DNA segments of the Ll gene that are bracketed by the MY09/11 primers were selected and compiled in a file A.
[23] 2) A file B was created, which included the set of following restriction en- donucleases: Pstl (5'-CTGCA/G-3'), HaeIII (5'-GG/CC-3'), Rsal (5'-GT/AC-3') and Ddel (5'-C/TNAG-3').
[24] This set of enzymes was pre-selected through an in silico analysis and allows identification of the 49 MY09/11 segments corresponding to the 49 reference HPV types.
[25] 3) Using the 'Restriction site analysis tool' of CLC Free Workbench program, the information of files A and B was crossed in order to predict the RFLP fragment sizes of each MY-amplicon restriction (Table 1).
[27] In table 1 , restriction fragments larger than 40 bp are in bold. Fragments under this size are not considered for discrimination of HPV types, because they are not visualized with good resolution in polyacrylamide or agarose gels. The superscript letters in Table 1 (a, b, and c) show HPV variants that have an altered RFLP-pattern with regards to their respective reference HPV type.
[28] The computer simulation showed that the use of Ddel, Haelll, Pstl, and Rsal, in four independent reactions, allows the complete genotyping of all mucosal HPV types. Each HPV type has a specific set of RFLP patterns, which is not shared by any other HPV type and can be clearly identified by visual discrimination in 10% polyacrylamide or in 3% agarose gels, except for one particular situation (case of HPV 85 and b variant of HPV 82), in which the size of the restriction fragments differed only by 9 bp. In this specific case, the problem can be solved using a 20% polyacrylamide gel, using type-specific PCR or by sequencing this MY09/11 amplicon.
[29] 4) Finally, based on the 74 sets of RFLP-patterns obtained for each HPV type (Table 1) and in the fact that each restriction enzyme does not cut some of MY09/11 amplicons, a genotyping scheme was developed.
[30] In Figure 2, where this genotyping scheme is defined, each box represents a restriction reaction using a specific enzyme. Draw lines represent the possible results when restriction does not occur, whereas dashed lines represent the possible results when restriction occurs. In two particular situations (designated by 1 and 2), draw lines also represent the possible results when restriction reaction originates an RFLP- fragment larger than 420 bp.
[31] The HPV type is identified in two easy steps: (1) sequential analysis of occurrence/ non-occurrence of Pstl, Haelll, Ddel and Rsal restriction reactions and (2) subsequent comparison of the restriction fragments obtained by Rsal digestion with the expected sizes (in brackets) defined for each HPV type by in silico analysis.
[32] In cases in which Rsal digestion does not occur (groups B, C and H), or when two or more HPVs present similar Rsal-RFLP patterns (groups A, D, E, F, G, I), HPV type
can be identified by comparison of the restriction fragment sizes obtained by Ddel or HaeIII restriction digestion ('confirmation pattern'). When a HPV type is identified, it is possible to confirm it, comparing all the RFLP-patterns obtained with data described in Table 1.
[33] One of the weak points of known HPV diagnostic assays is the appearance of false negatives, due to the poor quality of DNA or by the presence of PCR inhibitors. In the present invention, a control consisting of parallel amplification of the patient's own DNA is used to ensure the quality of DNA sample. Primers Beta 1 and Beta 2 (SEQ ID NO 21 and 22) were designed for amplification of a 501 bp fragment from beta-globin gene. However, any sequence fragment from human DNA can be used as target for this purpose.
[34] An additional control is performed to test the efficacy of each enzyme and to avoid the misidentification of types due to partial digestion, based in a parallel co-digestion of MY09/11 amplification products with the control DNA (product of beta-globin fragment amplification). Betal/2 amplicon is cleaved by the whole spectrum of selected restriction enzymes when optimal conditions are achieved, originating the following restriction fragments: Pstl: 322 bp + 179 bp; HaeIII: 279 bp + 222 bp; Ddel: 271 bp + 198 bp + 32 bp; Rsal: 251 bp + 210 bp + 40 (see Figure 3). The size of these fragments does not coincide with any of the fragments listed in Table 1.
[35] In conclusion, the present invention offers significant advantages, not only over the
PCR-RFLP techniques previously described, but also over other currently available HPV typing assays (like hybridization with type-specific probes, type-specific PCR, microarray methodologies): 1) it detects a higher number of HPV types (49 HPV types and 2 HPV subtypes); 2) it allows the individual detection of all known and unknown HPV types; and 3) it can be performed using standard laboratorial equipment and in settings of poor financial resources.
[36] Another aspect of the present invention also relates to an in vitro diagnostic kit for identification of HPV types. This kit comprises the following components:
- a standard nucleic acid amplification mix with universal HPV primers;
- 4 different restriction reaction vessels (each one contains a specific restriction enzyme and respective buffers) ;
- a HPV genotyping scheme for an accurate processing of results
[37] In a preferred embodiment of the invention, the above-mentioned kit also comprises a standard nucleic acid amplification mix with a pair of primers to test DNA integrity.
[38] In other preferred embodiment of the invention the said kit may also comprise a positive and negative control sample.
[39] Finally, the kit also may include instructions for its use.
[40] Examples
EXAMPLE 1 : DNA extraction from cells of the cervix uteri - Cervical cells collected from the cervix uteri, using a brush or spatula, were resuspended in PreservCyt solution (Cytyc Corporation. Boxborough, MA. USA). An aliquot of 5ml was cen- trifuged at 10.000 rpm for 15 min. The pelleted cells were lysed in a Tris-buffered solution (0.3M NaCl, 1OmM EDTA, 10mM Tris pH 7.5), containing 0.5% SDS and 0.5μg/μl of proteinase K, at 56 ºC. The DNA was purified by standard phenol/ chloroform extraction and ethanol precipitation.
[41] EXAMPLE 2: Human papillomavirus detection - HPV DNA was detected by PCR using the degenerate consensus primers MY09/11 (Manos et al. Cold Spring Harbor Press. 1989, 7:209-214), which amplify a region of 449-458 nucleotides (depending on HPV type) of the highly conserved Ll ORF. Each PCR amplification was carried out with lOOng of template DNA in 1x PCR Buffer (Biotools, Madrid, Spain), containing 1.5mM MgC12, 12.5 pmol of each primer MY09 and MYl 1 (SEQ ID NO 1 and 2), 200 uM of each deoxynucleotide triphosphate and 1 unit of Taq DNA polymerase (Biotools, Madrid, Spain). Thermal cycling was performed in a Perkin-Elmer 9600 (PerkinElmer, MA, USA) as follows: denaturation of DNA template at 95 ºC for 5 min, followed by 45 cycles of 94 ºC for 60 sec, 55 ºC for 60 sec, and 72 ºC for 60 sec, and a final extension step at 72 ºC for 8 min. To check the integrity of the DNA extracted from the specimens, a region of 501 base pairs of the cellular Beta-globin gene was amplified using primers Betal and Beta2 (SEQ ID NO 21 and 22). The PCR conditions were the same as described for HPV detection. All PCR reactions were carried out under conditions that minimize sample cross-contamination. DNA from HeLa and CaSki cell lines was used as positive control. A negative control containing all PCR reagents, except the DNA, was added to monitor contamination. In order to verify the amplification efficiency of PCR reactions and the absence of unspecific products, the amplified DNA was analyzed in a horizontal 2% agarose gel, pre-stained with Gel Star (Cambrex Bio Science Rockland, Inc., ME, USA) and visualized on a UV screen.
[42] EXAMPLE 3: Human papillomavirus genotyping - MY09/11-positive cases were typed by RFLP analysis in 4 independent reactions. Each restriction reaction was performed in a final volume of 20 μl, using 1 μg of MY09/11 PCR product, 2 μl of 10x recommended restriction buffer, and 10 units of the following restriction en- donucleases: Pstl (Qbiogene, CA, USA), HaeIII (Fermentas Inc., Canada), Ddel (Qbiogene, CA, USA) and Rsal (Fermentas Inc., Canada), according to the manufacturers' instructions. Reactions took place at 37 ºC for 1 h. Digested products were electrophoretically separated on 10% polyacrylamide gels, in the presence of 25 bp and 50 bp DNA molecular weight markers (Invitrogen, Carlsbad, CA, USA). Gels were stained with Gelstar (Cambrex Bio Science Rockland, Inc., ME, USA) for 15 min and
patterns were visualized using a Versa Doc Imaging System (Bio-Rad. Hercules. CA, USA). The identification of HPV type(s) was performed using a genotyping scheme (Figure 2).
[43] EXAMPLE 4: Validation of RFLP restriction reaction - To test the efficacy of each enzyme and to avoid the misidentification of types due to partial digestion, an additional restriction reaction was performed, in which MY09/11 PCR products and a control DNA (PCR product of Beta-globin fragment amplification) were digested together. Each restriction reaction was performed in a final volume of 20 μl, using 1 μg of MY09/11 PCR product. 1 μg of Betal/2 amplicon, 2 μl of 10x recommended restriction buffer, and 20 units of each restriction endonuclease, according to the conditions described in Example 3.
[44] EXAMPLE 5: Clinical validation of the present invention - To confirm the reliability of the present PCR-RFLP based methodology and the applicability of the HPV typing scheme in HPV identification, two different experiments were performed. The first study was carried out, in a blind fashion, on pre-selected HPV positive clinical samples, in which 27 different mucosal HPV types had been previously identified by PCR with MY09/11 primers and DNA sequencing (HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 44, 45, 52, 53, 56, 58, 59, 61, 62, 66, 67, 70, 71, 73, 81, 83, 84, and 102). In all samples, PCR-RFLP data consistently matched the DNA sequencing results. Figure 4 shows the RFLP patterns of some HPV types (HPV 16, HPV 58 and HPV 102).
[45] The second study, which has consisted in a random and blind experiment, was performed on a representative collection of 30 untyped clinical samples (10 normal samples, 10 low-grade squamous intraepithelial lesions, 5 high-grade squamous intraepithelial lesions and 5 invasive cervical carcinoma samples). Of the 30 cervical samples analyzed, HPV DNA was detected in 16 cases (3/10 normal samples, 3/10 low grade-lesions, 5/5 high grade-lesions and 5/5 carcinoma samples). Corresponding MY09/11 PCR products were subsequently genotyped using both the present invention and DNA sequencing/cloning technique. In the last, PCR products were purified from agarose gel using a PCR clean-up Gel extraction Kit (NucleoSpin® Extract II, Macherey-Nagel, Geπnany) and cloned. At least, five fragments of each amplicon were sequenced. Forward and reverse sequencing reactions were carried out using 20 ng of template DNA from PCR amplimers and 20 μM of the MY09 and MYl 1 primers, respectively. Automated DNA sequencing was performed by Eurofins MWG Operon (Ebersberg, Germany). Sequences obtained were compared with all sequences available in Gen-Bank database. HPV type was identified based on >98% sequence homology over 449-458 nucleotides. Table 2 shows the comparative genotyping results of HPV-positive clinical samples using RFLP analysis and DNA sequencing/ cloning analysis of MY09/1 1 PCR products.
[46] Table 2:
[47] In Table 2, accession numbers of DNA sequences are given in brackets. Letter S means single infection and M means multiple infections.
[48] RFLP data consistently matched the DNA sequencing results, with the exception of one single case, sample 22, in which it was impossible to discriminate the triple HPV infection using RFLP analysis, due to the complexity of the pattern obtained. Nevertheless, in all other HPV-positive samples, even in the case of multiple infections (e.g. samples 16 and 23), sequencing results confirmed RFLP genotyping. AU the enzymes have shown a high cutting efficiency and no partial digestions were visualized under the RFLP conditions previously described.
Claims
[1] An assay for detection and individual identification of human papillomavirus (HPV) in a sample, which comprises the steps of: a) amplifying the DNA using HPV universal primers; b) analyzing the amplified fragment in independent restriction reactions; and c) identifying HPV type by comparison of the RFLP patterns with the reference patterns of known genotypes, characterized by step b) being conducted in 4 independent reactions with different restriction enzymes, namely Pstl, Haelll, Ddel and Rsal, and step c) being performed with the genotyping scheme of figure 2.
[2] The assay, according to claim 1. wherein the restriction products are analyzed in agarose or polyacrylamide gels pre-stained with a nucleic stain for DNA, being the concentration of the agarose at least of 3% and the concentration of polyacrylamide at least 10% in the respective gels.
[3] The assay, according to claims 1 or 2, wherein restriction products are analyzed in polyacrylamide gels pre-stained with a nucleic stain for DNA, wherein the concentration of said polyacrylamide gels is higher than 10% and up to 20%.
[4] The assay, according to any of claims 1 to 3, further comprising an amplification of human DNA in a sample.
[5] The assay, according to claim 4 wherein the sample of the DNA amplified was collected from the same origin as the tested sample.
[6] The assay, according to any of claims 1 to 5 further comprising a parallel co-digestion of the HPV DNA amplification products with the control DNA.
[7] A kit for performing the method of any of the claims 1 to 6, comprising the following components:
- a standard nucleic acid amplification mix with universal HPV primers;
- 4 different restriction reaction vessels each one comprising a specific restriction enzyme and respective buffers;
- a HPV genotyping scheme.
[8] A kit, according to claim 7, further comprising a standard nucleic acid amplification mix with a pair of primers to test DNA integrity.
[9] A kit, according to any of claims 7 or 8, further comprising the positive and negative control samples.
[10] A genotyping scheme according to figure 2.
[11] A genotyping scheme according to claim 10, wherein the HPV type is identified through the below described steps:
- first, following the dashed or draw lines, according to the occurrence or non- occurrence of Pstl. HaeIIL Ddel and Rsal restriction reactions, respectively.
- secondly, by comparison of the restriction fragments obtained by Rsal digestion with the expected sizes defined for each HPV type, at the end of the scheme,
- in cases marked with caps letters, HPV type is identified by comparison of the restriction fragment sizes obtained by Ddel or HaeIII restriction digestion
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3744208P | 2008-03-18 | 2008-03-18 | |
US61/037,442 | 2008-03-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009116884A2 true WO2009116884A2 (en) | 2009-09-24 |
WO2009116884A3 WO2009116884A3 (en) | 2009-11-19 |
Family
ID=41050972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PT2009/000015 WO2009116884A2 (en) | 2008-03-18 | 2009-03-18 | Human papillomavirus detection kit |
Country Status (2)
Country | Link |
---|---|
PT (1) | PT2009116884W (en) |
WO (1) | WO2009116884A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103320533A (en) * | 2013-06-26 | 2013-09-25 | 清华大学 | HPV (human papillomavirus) DNA (deoxyribonucleic acid) genetic typing method and kit thereof |
CN103361442A (en) * | 2013-07-01 | 2013-10-23 | 陈玲瀚 | Method and kit for detecting HPV (Human Papillomavirus) genotype |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814448A (en) * | 1991-07-19 | 1998-09-29 | The Trustees Of Columbia University In The City Of New York | Polymerase chain reaction/restriction fragment polymorphism method for the detection and typing of human papillomaviruses |
-
2009
- 2009-03-18 PT PT2009000015A patent/PT2009116884W/en unknown
- 2009-03-18 WO PCT/PT2009/000015 patent/WO2009116884A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814448A (en) * | 1991-07-19 | 1998-09-29 | The Trustees Of Columbia University In The City Of New York | Polymerase chain reaction/restriction fragment polymorphism method for the detection and typing of human papillomaviruses |
Non-Patent Citations (5)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 1998 (1998-07), ZHANG QIUPING ET AL: "Detecting and typing of human papillomaviruses in rectal carcinoma tissues by polymerase chain reaction with consensus primers and restriction fragment length polymorphism" XP002545753 Database accession no. PREV199900060187 & ACTA ACADEMIAE MEDICINAE HUBEI, vol. 19, no. 3, July 1998 (1998-07), pages 193-196, ISSN: 1000-243X * |
GRAVITT P E ET AL: "Improved amplification of genital human papillomaviruses" JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 38, no. 1, 1 January 2000 (2000-01-01), pages 357-361, XP002490517 ISSN: 0095-1137 cited in the application * |
MEYER T ET AL: "Strategy for typing human papillomaviruses by RFLP analysis of PCR products and subsequent hybridization with a generic probe" BIOTECHNIQUES, vol. 19, no. 4, 1995, pages 632-639, XP009122660 ISSN: 0736-6205 * |
MILUTIN N ET AL: "Evaluation of RFLP, DNA sequencing, PCR-SSCP and line probe assay for HPV genotyping." EJC SUPPLEMENTS, vol. 1, no. 5, September 2003 (2003-09), page S300, XP009122633 & 12TH ECCO (EUROPEAN CANCER CONFERENCE); COPENHAGEN, DENMARK; SEPTEMBER 21-25, 2003 ISSN: 1359-6349 * |
NOBRE RUI JORGE ET AL: "Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm." JOURNAL OF CLINICAL VIROLOGY : THE OFFICIAL PUBLICATION OF THE PAN AMERICAN SOCIETY FOR CLINICAL VIROLOGY MAY 2008, vol. 42, no. 1, May 2008 (2008-05), pages 13-21, XP002545752 ISSN: 1386-6532 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103320533A (en) * | 2013-06-26 | 2013-09-25 | 清华大学 | HPV (human papillomavirus) DNA (deoxyribonucleic acid) genetic typing method and kit thereof |
CN103361442A (en) * | 2013-07-01 | 2013-10-23 | 陈玲瀚 | Method and kit for detecting HPV (Human Papillomavirus) genotype |
CN103361442B (en) * | 2013-07-01 | 2015-04-01 | 宋宁 | Method and kit for detecting HPV (Human Papillomavirus) genotype |
Also Published As
Publication number | Publication date |
---|---|
WO2009116884A3 (en) | 2009-11-19 |
PT2009116884W (en) | 2013-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nobre et al. | Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm | |
Josefsson et al. | Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay | |
US8980555B2 (en) | Rapid genotyping analysis and devices thereof | |
JP5595276B2 (en) | New detection method for cervical HPV | |
WO2006075245A2 (en) | Systems, methods, and compositions for detection of human papilloma virus in biological samples | |
CA2617978A1 (en) | In vitro diagnostic kit for identification of human papillomavirus in clinical samples | |
WO2012094682A2 (en) | Materials and method for genotyping and quantifying a high-risk human papillomavirus | |
Lee et al. | Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories | |
WO2010126375A1 (en) | A method for detection of human papillomavirus (hpv) type | |
Williamson et al. | Detection of genital human papillomaviruses by polymerase chain reaction amplification with degenerate nested primers | |
CA2450164A1 (en) | Virus detection method, primers therefor and screening kit | |
Kónya et al. | Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopical atypia | |
Nobre et al. | Characterization of common and rare human papillomaviruses in Portuguese women by the polymerase chain reaction, restriction fragment length polymorphism and sequencing | |
EP1546413B1 (en) | Method and kit for quantitative and qualitative determination of human papillomavirus | |
Milutin Gašperov et al. | Detection and typing of human papillomaviruses combining different methods: polymerase chain reaction, restriction fragment length polymorphism, line probe assay and sequencing | |
WO2009116884A2 (en) | Human papillomavirus detection kit | |
Lowe et al. | HPV genotype detection using hybrid capture sample preparation combined with whole genome amplification and multiplex detection with Luminex XMAP | |
Tsakogiannis et al. | Duplex real-time PCR assay and SYBR green I melting curve analysis for molecular identification of HPV genotypes 16, 18, 31, 35, 51 and 66 | |
Laconi et al. | One-step detection and genotyping of human papillomavirus in cervical samples by reverse hybridization | |
Kocjan et al. | Universal ProbeLibrary based real-time PCR assay for detection and confirmation of human papillomavirus genotype 52 infections | |
WO2010033619A2 (en) | Systems, methods, and compositions for detection of human papilloma virus in biological samples | |
US20130116136A1 (en) | Probes for genotyping low-risk-hpv | |
SHERIF et al. | Molecular diagnosis of human papilloma virus infection | |
EP2362916B1 (en) | Hpv types and variants associated with cervical cancer and the uses thereof | |
US20070238100A1 (en) | Integrated methodologies for the detection and genotyping of human papillomaviruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09723268 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09723268 Country of ref document: EP Kind code of ref document: A2 |
|
REG | Reference to national code |
Ref country code: PT Ref legal event code: FG4A Effective date: 20130130 |